Finance

Lists
AUROPHARMA:NSE
Aurobindo Pharma Ltd
₹ १,६६६.९०
-०.६६%
(-११.००) 1D
अक्टोबर १६, १५:३०:०० GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AUROPHARMA...
Open
₹ १,६७७.९०
High
₹ १,६८१.७०
Low
₹ १,६५५.००
Mkt. cap
९.५९ खरब
Avg. vol.
७.७९ लाख
Volume
७.९७ लाख
P/E ratio
२६.०४
52-wk high
₹ १,७४०.००
52-wk low
₹ १,०८०.१०
EPS
₹ ६४.००
Shares outstanding
५८.५९ करोड
No. of employees
२९ हजार
Open
₹ १,६७७.९०
High
₹ १,६८१.७०
Low
₹ १,६५५.००
Mkt. cap
९.५९ खरब
Avg. vol.
७.७९ लाख
Volume
७.९७ लाख
P/E ratio
२६.०४
52-wk high
₹ १,७४०.००
52-wk low
₹ १,०८०.१०
EPS
₹ ६४.००
Shares outstanding
५८.५९ करोड
No. of employees
२९ हजार
News stories
From web sources and news partners
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees२९.२ हजार
Founded१९८६
Headquartersहैदराबाद, आन्ध्र प्रदेश, भारत
Sector-
Last report
२०२६ अगस्ट ६
Fiscal period
Q1 2027
₹ १७.४६ / ₹ १७.२६
+१.१७%beat
Revenue / Est. (INR)
९१.५० अरब / ८९.९८ अरब
+१.६९%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
८२.८६ अरब
८६.४६ अरब
८८.५३ अरब
९१.५० अरब
Cost of goods sold
३३.३९ अरब
३४.८१ अरब
३९.२८ अरब
३६.२७ अरब
Cost of revenue
३३.३९ अरब
३४.८१ अरब
३९.२८ अरब
३६.२७ अरब
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१२.७७ अरब
१३.१० अरब
१४.३१ अरब
१४.८० अरब
Operating expense
३६.९८ अरब
३८.५६ अरब
३५.२९ अरब
४१.२९ अरब
Total operating expenses
७०.३७ अरब
७३.३७ अरब
७४.५७ अरब
७७.५६ अरब
Operating income
१२.४९ अरब
१३.०९ अरब
१३.९६ अरब
१३.९४ अरब
Other non operating income
१.१६ अरब
१.५४ अरब
-२.५१ अरब
२.१२ अरब
EBT including unusual items
१२.७६ अरब
१३.३९ अरब
१२.९१ अरब
१५.१५ अरब
EBT excluding unusual items
१२.७६ अरब
१४.०४ अरब
१३.५९ अरब
१५.५५ अरब
Income tax expense
४.२८ अरब
४.२९ अरब
३.७० अरब
४.८३ अरब
Effective tax rate
३३.५३%
३२.०३%
२८.६५%
३१.८८%
Other operating expenses
१९.९१ अरब
२०.८१ अरब
१६.३७ अरब
२१.६२ अरब
Net income
८.४८ अरब
९.१० अरब
९.२१ अरब
१०.३३ अरब
Net profit margin
१०.२४%
१०.५३%
१०.४१%
११.२८%
Earnings per share
१४.६१
१६.४३
१५.८६
१७.४६
Interest and investment income
-
-
३.३१ अरब
-
Interest expense
-९५.२४ करोड
-९२.७७ करोड
-६६.५५ करोड
-१.०२ अरब
Net interest expenses
-९५.२४ करोड
-९२.७७ करोड
२.६५ अरब
-१.०२ अरब
Depreciation and amortization charges
४.२९ अरब
४.६५ अरब
४.६१ अरब
४.८७ अरब
EBITDA
१६.६६ अरब
१६.७१ अरब
१८.०३ अरब
१८.०१ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google एपहरू